A药品名称: B药品名称: B与A对换
 药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
A药品
B药品
详细
Quinethazone
Quinoline Yellow WS
The risk or severity of hypotension, hyperkalemia, and nephrotoxicity can be increased when Aliskiren is combined with Quinoline Yellow WS.
Quinethazone
Quinaprilat
The risk or severity of hypotension, hyperkalemia, and nephrotoxicity can be increased when Aliskiren is combined with Quinaprilat.
Quinethazone
Perindoprilat
The risk or severity of hypotension, hyperkalemia, and nephrotoxicity can be increased when Aliskiren is combined with Perindoprilat.
Quinethazone
Moexiprilat
The risk or severity of hypotension, hyperkalemia, and nephrotoxicity can be increased when Aliskiren is combined with Moexiprilat.
Quinethazone
Trandolaprilat
The risk or severity of hypotension, hyperkalemia, and nephrotoxicity can be increased when Aliskiren is combined with Trandolaprilat.
Quinethazone
Ramiprilat
The risk or severity of hypotension, hyperkalemia, and nephrotoxicity can be increased when Aliskiren is combined with Ramiprilat.
Quinethazone
Fosinoprilat
The risk or severity of hypotension, hyperkalemia, and nephrotoxicity can be increased when Aliskiren is combined with Fosinoprilat.
Quinethazone
Benazeprilat
The risk or severity of hypotension, hyperkalemia, and nephrotoxicity can be increased when Aliskiren is combined with Benazeprilat.
Quinethazone
Delapril
The risk or severity of hypotension, hyperkalemia, and nephrotoxicity can be increased when Aliskiren is combined with Delapril.
Quinethazone
Zofenopril
The risk or severity of hypotension, hyperkalemia, and nephrotoxicity can be increased when Aliskiren is combined with Zofenopril.
Quinethazone
Imidapril
The risk or severity of hypotension, hyperkalemia, and nephrotoxicity can be increased when Aliskiren is combined with Imidapril.
Quinethazone
Enalaprilat
The risk or severity of hypotension, hyperkalemia, and nephrotoxicity can be increased when Aliskiren is combined with Enalaprilat.
Quinethazone
Naxitamab
Naxitamab may decrease the antihypertensive activities of Aliskiren.
Quinethazone
Selpercatinib
Selpercatinib may decrease the antihypertensive activities of Aliskiren.
Quinethazone
Terguride
Terguride may decrease the antihypertensive activities of Aliskiren.
Quinethazone
Dihydroergocryptine
Dihydroergocryptine may decrease the antihypertensive activities of Aliskiren.
Quinethazone
Dihydroergocristine
Dihydroergocristine may decrease the antihypertensive activities of Aliskiren.
Quinethazone
Levosalbutamol
Levosalbutamol may decrease the antihypertensive activities of Aliskiren.
Quinethazone
Siponimod
Siponimod may decrease the antihypertensive activities of Aliskiren.
Quinethazone
Propiverine
Propiverine may decrease the antihypertensive activities of Aliskiren.
免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究  客服热线:0575-83552251 / 13754370441  QQ客服:药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证:浙B2-20220931 互联网药品信息服务资格证书编号:(浙)-经营性2023-0215 浙公网安备:330683240604819103159
 医药代理商群1:药药网药品采购交流医药代理商群2:药药网药品采购交流2医药代理商群3:药药网药品采购交流3